Patents by Inventor Dominik Haudenschild

Dominik Haudenschild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008054
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: April 30, 2020
    Publication date: January 14, 2021
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik HAUDENSCHILD, Paul DI CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Patent number: 10639302
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 5, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Publication number: 20200046726
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: May 23, 2019
    Publication date: February 13, 2020
    Inventors: Dominik HAUDENSCHILD, Jasper YIK
  • Publication number: 20190255034
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: November 20, 2018
    Publication date: August 22, 2019
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Patent number: 10300073
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 28, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Jasper Yik
  • Patent number: 10172844
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Publication number: 20170304315
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: October 13, 2015
    Publication date: October 26, 2017
    Applicant: The Regents of the University of California
    Inventors: Dominik HAUDENSCHILD, Jasper YIK
  • Publication number: 20170246156
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: November 18, 2016
    Publication date: August 31, 2017
    Applicant: The Regents of the University of California
    Inventors: Dominik HAUDENSCHILD, Paul Di CESARE, Jasper YIK, Blaine CHRISTIANSEN
  • Patent number: 9498471
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 22, 2016
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Patent number: 9133259
    Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 15, 2015
    Assignee: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
  • Publication number: 20150105423
    Abstract: The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: October 19, 2012
    Publication date: April 16, 2015
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik, Blaine Christiansen
  • Publication number: 20130315889
    Abstract: The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and/or osteogenesis, and repair of cartilage and bone lesions.
    Type: Application
    Filed: September 14, 2011
    Publication date: November 28, 2013
    Applicant: The Regents of the University of California
    Inventors: Dominik Haudenschild, Paul Di Cesare, Jasper Yik
  • Publication number: 20040171109
    Abstract: This invention relates, first, to the discovery of IL-17RL, a receptor for members of the IL-17 cytokine family, particularly IL-17B. IL-17RL is naturally expressed from a 19-exon gene as a 720 amino acid protein and as any of 11 splice variants created from differential splicing of the 19 exons. The invention further relates to the discovery that IL-17B is involved in catabolic degradation of bone and cartilage and that bone and cartilage disorders can be ameliorated by pharmacological manipulation of IL-17B by antibodies or by using IL-17RL as a decoy to reduce IL-17B related catabolic activity. Methods for diagnosing cartilage disorders, and pharmaceutical compositions for slowing or ameliorating bone and cartilage pathologies are also provided.
    Type: Application
    Filed: September 16, 2003
    Publication date: September 2, 2004
    Inventors: Dominik Haudenschild, Larry Rose, Timothy Moseley, A. Hari Reddi